Mycamine, known generically as micafungin, is an antifungal medication used in the treatment and prevention of certain fungal infections, particularly those caused by Candida species, including candidemia, esophageal candidiasis, and prophylaxis against Candida infections in patients undergoing hematopoietic stem cell transplantation. It belongs to the class of drugs known as echinocandins, which work by inhibiting the synthesis of β-1,3-D-glucan, an essential component of the fungal cell wall, thereby exerting a fungicidal effect. Mycamine is administered intravenously, and its use is generally well-tolerated, although some patients may experience side effects such as headache, nausea, or infusion-related reactions. Due to its mechanism of action and spectrum of activity, Mycamine is a valuable option in the management of serious fungal infections, particularly in settings where other antifungal therapies are not suitable or have failed.